News Breaks |
|
|
| October 11, 2012 |
| 12:55 EDT |  | GILD, GILD, GILD, IDIX, IDIX, IDIX, JNJ, JNJ, JNJ, MRK, MRK, MRK, VRTX, VRTX, VRTX, ABT, ABT, ABT, ACHN, ACHN, ACHN, BMY, BMY, BMY | Leerink's major pharmaceuticals and biotech analysts hold a conference call
Biotech Analyst Liang and Major Pharmaceuticals Analyst Fernandez discuss their impressions of Bristol-Myers Squibb/Gilead Sciences' data from the 12-week combination of daclastavir + sofosbuvir (GS-7977), comparison of the advantages and disadvantages of ABT and GILD regimens, as well as outlook for other interferon-free regimens in development on an Analyst/Industry conference call. Relevant covered companies ABT, ACHN, BMY, GILD, IDIX, JNJ, MRK and VRTX may be discussed on the Analyst/Industry conference call to be held on October 15 at 1 pm. |
|
|
News For ABT;ACHN;BMY;GILD;IDIX;JNJ;MRK;VRTX From The Last 14 Days Check below for free stories on ABT;ACHN;BMY;GILD;IDIX;JNJ;MRK;VRTX the last two weeks. |
|
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
 Subscribe for More Information |
|
| 06:19 EDT |  | JNJ | J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT |  | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| 10:30 EDT | | ACHN | Achillion management to meet with Maxim
Subscribe for More Information |
|
| 08:55 EDT | | MRK, BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT |  | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
| |
| May 15, 2013 |
| 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information |
|
| 16:51 EDT | | JNJ | FDA approves Simponi to treat ulcerative colitis
Subscribe for More Information |
|
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 09:43 EDT | | BMY | Active equity option families trading on open
Subscribe for More Information |
|
| 06:06 EDT | | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. |
|
| May 14, 2013 |
| 17:39 EDT | | MRK | Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook
Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. |
|
| 07:24 EDT | | BMY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 13, 2013 |
| 09:39 EDT | | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR |
|
| May 10, 2013 |
| 14:02 EDT | | VRTX | Vertex to benefit from Welsh government decision, says Wells Fargo
Subscribe for More Information |
|
| 11:48 EDT | | BMY, MRK, JNJ | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
| |
|
|
|
|
